Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ADCT
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | W. Lawrence Hawkins | 399,900 | 0.3% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Plus Fund, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Partners, LLC | 399,900 | 0.3% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Management, LP | 399,900 | 0.3% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Fund, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Oct 29, 2026 | SCHEDULE 13G | ADCT ADC Therapeutics SA | Bain Capital Life Sciences Opportunities IV, L.P. | 14.83M | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | ADCT ADC Therapeutics SA | Daniel Mack | 12.33M | 9.7% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | ADCT ADC Therapeutics SA | Wilmot B. Harkey | 12.33M | 9.7% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | ADCT ADC Therapeutics SA | Nantahala Capital Management, LLC | 12.33M | 9.7% | SCHEDULE 13G ↗ |
| Jul 27, 2026 | SCHEDULE 13G | ADCT ADC Therapeutics SA | BlackRock, Inc. | 6.86M | 5.4% | SCHEDULE 13G ↗ |
| Apr 24, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | RedCo II Master Fund, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 24, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | RedCo II Offshore SPV LLC | 7.78M | 6.1% | SCHEDULE 13G/A ↗ |
| Apr 24, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Jeremy C. Green | 12.72M | 9.9% | SCHEDULE 13G/A ↗ |
| Apr 24, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Redmile Group, LLC | 12.72M | 9.9% | SCHEDULE 13G/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | RedCo II Master Fund, L.P. | 10.28M | 8.1% | SCHEDULE 13G/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Jeremy C. Green | 12.69M | 9.9% | SCHEDULE 13G/A ↗ |
| Apr 6, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Redmile Group, LLC | 12.69M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | ADCT ADC Therapeutics SA | Chen Yu | 11.39M | 9.2% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | ADCT ADC Therapeutics SA | TCG Crossover Fund II, L.P. | 11.39M | 9.2% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | ADCT ADC Therapeutics SA | TCG Crossover GP II, LLC | 11.39M | 9.2% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | RedCo II Master Fund, L.P. | 13.15M | 10.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Jeremy C. Green | 15.67M | 12.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Redmile Group, LLC | 15.67M | 12.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Orbimed Capital LLC | 3.23M | 2.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Orbimed Advisors LLC | 2.59M | 2.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Steven A. Cohen | 5.01M | 4.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Point72 Capital Advisors, Inc. | 5.01M | 4.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Point72 Asset Management, L.P. | 5.01M | 4.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | W. Lawrence Hawkins | 8.48M | 6.8% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Partners, LLC | 8.48M | 6.8% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Plus Fund, LP | 1.85M | 1.5% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Fund, LP | 402,286 | 0.3% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Management, LP | 8.48M | 6.8% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | W. Lawrence Hawkins | 7.20M | 5.8% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Partners, LLC | 7.20M | 5.8% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Plus Fund, LP | 1.59M | 1.3% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Fund, LP | 350,415 | 0.3% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Prosight Management, LP | 7.20M | 5.8% | SCHEDULE 13G/A ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | BAM Partners Trust | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Brookfield Asset Management, Ltd. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Brookfield Corporation | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Brookfield Asset Management ULC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Oaktree Capital Group Holdings GP, LLC | 4.67M | 4.1% | SCHEDULE 13G/A ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Oaktree Capital Holdings, LLC | 4.67M | 4.1% | SCHEDULE 13G/A ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Oaktree Fund Administration, LLC | 4.67M | 4.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | RedCo II Master Fund, L.P. | 13.15M | 11.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Jeremy C. Green | 15.67M | 14.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ADCT ADC Therapeutics SA | Redmile Group, LLC | 15.67M | 14.0% | SCHEDULE 13G/A ↗ |
| Jun 17, 2025 | SCHEDULE 13G | ADCT ADC Therapeutics SA | Steven A. Cohen | 7.83M | 7.0% | SCHEDULE 13G ↗ |
| Jun 17, 2025 | SCHEDULE 13G | ADCT ADC Therapeutics SA | Point72 Capital Advisors, Inc. | 7.83M | 7.0% | SCHEDULE 13G ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:50 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances